FROM MOLECULE...TO HUMAN
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
SPI researchers (Marcoule) used proteomics to identify signature peptides of the SARS-CoV-2 virus expressed in vitro. A "short list" of 14 identified and characterized peptides allows to consider developments in targeted mass spectrometry, making this direct and rapid large-scale approach, implantable in hospitals, a potential tool of choice in the detection of the virus responsible for Covid-19.
A team from SCBM, in collaboration with researchers from I2BC, SHFJ and IRAMIS, has synthesized new neutral macrocycles called bambusurils (BUs). These BUs can be functionalized by “click chemistry” to obtain multivalent architectures decorated with 8 to 12 ligands of interest, an alternate topology which gives them remarkable supramolecular properties.
Researchers from the SCBM in collaboration with teams from IRAMIS, AstraZeneca and the Karolinska Institutet have developed a second marking method based on the dynamic exchange of carbon dioxide, this time without catalysis, by "simple" thermal heating. Ideal for organic molecules of therapeutic interest, the method is described in tAngewandte Chemie.
A collaboration led by I2BC researchers presents, in the Journal of Experimental Botany, a body of evidence for a dynamic association of the PTOX protein with thylakoid membranes, dependent on proton motive force.
In a study conducted by a team from the Institut Curie, I2BC researchers have used their NMR know-how to study the phosphorylation of BRCA2 and have thus contributed to revealing a mechanism potentially at the origin of chromosomal aberrations observed in breast BRCA2-mutated tumors.
A collaboration between researchers from I2BC@Saclay, the french Muséum National d'Histoire Naturelle and owners of prehistoric sites shows the possibility of using a mobile laboratory to quickly identify DNA of archaeological specimens.
Researchers at the "Laboratoire Innovations technologiques pour la Détection et le Diagnostic" (LI2D, in Marcoule) of the Department of Medicines and Technologies for Health (DMTS) have developed a mathematical method to identify in a metaproteomics dataset the contribution of each of the organisms that make up a microbiota. This robust method, called phylopeptidomics, is described in the journal Microbiome.
A study conducted by a multidisciplinary team from NeuroSpin, in collaboration with researchers from the AP-HP (Hôpitaux Universitaires St Louis-Lariboisière-F Widal), reveals for the first time, by 7Tesla MRI of Lithium-7, an accumulation of Lithium in the left hippocampus of patients with bipolar disorder and treated with Lithium. These results should help to better understand the therapeutic response to this drug.
Two recent studies conducted by SPI researchers, in collaboration with Inserm and AP/HP teams, reveal the value of measuring plasma levels of calgranulins as biomarkers for the prediction of mortality risk of patients with septic shock, admitted in intensive care unit.
Researchers from SIMoS, SCBM and Institut Curie, in collaboration with Carnegie Mellon University (USA), have identified the intracellular target and the mechanism of action of Retro-2, a broad-spectrum inhibitor of intracellular toxins and pathogens. They are now working on the design of an effective drug in the event of a bioterrorist attack or a health crisis.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.